{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,11]],"date-time":"2026-06-11T02:23:52Z","timestamp":1781144632942,"version":"3.54.1"},"reference-count":34,"publisher":"BMJ","issue":"11","license":[{"start":{"date-parts":[[2025,11,9]],"date-time":"2025-11-09T00:00:00Z","timestamp":1762646400000},"content-version":"unspecified","delay-in-days":8,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100004622","name":"Dutch Cancer Society","doi-asserted-by":"crossref","award":["grant number 12413"],"award-info":[{"award-number":["grant number 12413"]}],"id":[{"id":"10.13039\/501100004622","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ Open"],"accepted":{"date-parts":[[2025,10,23]]},"published-print":{"date-parts":[[2025,11]]},"abstract":"<jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>The currently available immunotherapies have failed to meet expectations in inducing durable responses in patients with advanced epithelial ovarian cancer (EOC). The low number of somatic missense mutations in EOC necessitates highly potent neoantigen-directed approaches. To this end, we have developed a novel dendritic cell (DC) product that consists of a specialised cross-presenting subset of DC, conventional DC type 1 (cDC1).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods and analysis<\/jats:title>\n                    <jats:p>We will conduct the NEODOC study, an investigator-initiated first-in-human phase I\/II trial. This study will assess the immunogenicity, safety and feasibility of a cDC1-based, autologous tumour lysate-loaded, DC product. 10 patients with previously untreated advanced EOC (stage IIIb-c, IVa or stage IVb if only supradiaphragmatic or inguinal lymph nodes &lt;1\u2009cm) requiring neoadjuvant chemotherapy will receive DC therapy alongside standard-of-care carboplatin\/paclitaxel chemotherapy and interval cytoreductive surgery. The primary endpoint is immune response, and the secondary endpoints are the safety and feasibility of the treatment as well as clinical efficacy.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Ethics and dissemination<\/jats:title>\n                    <jats:p>Ethical approval for this trial was granted by the Netherlands Central Committee on Research Involving Human Subjects. The results will be disseminated through publications in international, open-access scientific journals and presentations at scientific conferences.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Trial registration number<\/jats:title>\n                    <jats:p>\n                      <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"clintrialgov\" xlink:href=\"NCT05773859\">NCT05773859<\/jats:ext-link>\n                      ; EUCT number 2024-512353-24-01.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1136\/bmjopen-2025-102184","type":"journal-article","created":{"date-parts":[[2025,11,10]],"date-time":"2025-11-10T05:45:34Z","timestamp":1762753534000},"page":"e102184","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":4,"title":["NEOadjuvant Dendritic cell therapy added to first line standard of care in advanced epithelial Ovarian Cancer (NEODOC): protocol of a first-in-human, exploratory, single-centre phase I\/II trial in the Netherlands"],"prefix":"10.1136","volume":"15","clinical-trial-number":[{"clinical-trial-number":"nct05773859","registry":"10.18810\/clinical-trials-gov"}],"author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7224-1036","authenticated-orcid":false,"given":"Bouke","family":"Koeneman","sequence":"first","affiliation":[{"name":"Department of Medical BioSciences, Radboud University Medical Center, Nijmegen, The Netherlands"},{"name":"Department of Medical Oncology, Radboud University Medical Center, Nijmegen, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0156-8365","authenticated-orcid":false,"given":"Gerty","family":"Schreibelt","sequence":"additional","affiliation":[{"name":"Department of Medical BioSciences, Radboud University Medical Center, Nijmegen, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tjitske","family":"Duiveman - de Boer","sequence":"additional","affiliation":[{"name":"Department of Medical BioSciences, Radboud University Medical Center, Nijmegen, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kevin","family":"Bos","sequence":"additional","affiliation":[{"name":"Department of Medical BioSciences, Radboud University Medical Center, Nijmegen, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tom","family":"van Oorschot","sequence":"additional","affiliation":[{"name":"Department of Medical BioSciences, Radboud University Medical Center, Nijmegen, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeanette","family":"Pots","sequence":"additional","affiliation":[{"name":"Department of Medical BioSciences, Radboud University Medical Center, Nijmegen, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicole","family":"Scharenborg","sequence":"additional","affiliation":[{"name":"Department of Medical BioSciences, Radboud University Medical Center, Nijmegen, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annemiek","family":"de Boer","sequence":"additional","affiliation":[{"name":"Department of Medical BioSciences, Radboud University Medical Center, Nijmegen, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simone","family":"Hins - de Bree","sequence":"additional","affiliation":[{"name":"Department of Medical BioSciences, Radboud University Medical Center, Nijmegen, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4082-0498","authenticated-orcid":false,"given":"Nienke","family":"de Haas","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Pharmacology and Toxicology, Radboud University Medical Center, Nijmegen, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"de Goede","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Pharmacology and Toxicology, Radboud University Medical Center, Nijmegen, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Harm","family":"Westdorp","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Radboud University Medical Center, Nijmegen, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maaike","family":"van Ham","sequence":"additional","affiliation":[{"name":"Department of Obstetrics and Gynecology, Radboud University Medical Center, Nijmegen, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"I Jolanda M","family":"de Vries","sequence":"additional","affiliation":[{"name":"Department of Medical BioSciences, Radboud University Medical Center, Nijmegen, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Petronella B","family":"Ottevanger","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Radboud University Medical Center, Nijmegen, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2025,11,9]]},"reference":[{"key":"2025120413262961000_15.11.e102184.1","doi-asserted-by":"crossref","DOI":"10.7189\/jogh.14.04155","article-title":"Global burden of gynaecological cancers in 2022 and projections to 2050","volume":"14","author":"Zhu","year":"2024","journal-title":"J Glob Health"},{"key":"2025120413262961000_15.11.e102184.2","unstructured":"IKNL . Nederlandse Kankerregistratie (NKR) \/ Netherlands cancer registry (NCR)."},{"key":"2025120413262961000_15.11.e102184.3","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2023.07.011"},{"key":"2025120413262961000_15.11.e102184.4","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0908806"},{"key":"2025120413262961000_15.11.e102184.5","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(23)00396-0"},{"key":"2025120413262961000_15.11.e102184.6","doi-asserted-by":"crossref","DOI":"10.1186\/s13048-024-01362-y","article-title":"PARP inhibitor era in ovarian cancer treatment: a systematic review and meta-analysis of randomized controlled trials","volume":"17","author":"Barad\u00e1cs","year":"2024","journal-title":"J Ovarian Res"},{"key":"2025120413262961000_15.11.e102184.7","doi-asserted-by":"publisher","DOI":"10.1101\/gr.165985.113"},{"key":"2025120413262961000_15.11.e102184.8","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa020177"},{"key":"2025120413262961000_15.11.e102184.9","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2015.62.3397"},{"key":"2025120413262961000_15.11.e102184.10","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1038\/nature10166","article-title":"Integrated genomic analyses of ovarian carcinoma","volume":"474","author":"Bell","year":"2011","journal-title":"Nature New Biol"},{"key":"2025120413262961000_15.11.e102184.11","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.2019-0244"},{"key":"2025120413262961000_15.11.e102184.12","doi-asserted-by":"publisher","DOI":"10.1038\/s41568-019-0162-4"},{"key":"2025120413262961000_15.11.e102184.13","doi-asserted-by":"crossref","DOI":"10.3390\/vaccines9020085","article-title":"Cancer Vaccines: Antigen Selection Strategy","volume":"9","author":"Zhao","year":"2021","journal-title":"Vaccines (Basel)"},{"key":"2025120413262961000_15.11.e102184.14","doi-asserted-by":"publisher","DOI":"10.1038\/S41577-019-0210-Z"},{"key":"2025120413262961000_15.11.e102184.15","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1016\/j.ejca.2020.04.036","article-title":"Quantitative and qualitative impairments in dendritic cell subsets of patients with ovarian or prostate cancer","volume":"135","author":"Mastelic-Gavillet","year":"2020","journal-title":"Eur J Cancer"},{"key":"2025120413262961000_15.11.e102184.16","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2023.1119371","article-title":"Longitudinal analysis of DC subsets in patients with ovarian cancer: Implications for immunotherapy","volume":"14","author":"Mastelic-Gavillet","year":"2023","journal-title":"Front Immunol"},{"key":"2025120413262961000_15.11.e102184.17","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-15-1399"},{"key":"2025120413262961000_15.11.e102184.18","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.170.6.3306"},{"key":"2025120413262961000_15.11.e102184.19","doi-asserted-by":"crossref","DOI":"10.1186\/s40425-019-0580-6","article-title":"The clinical application of cancer immunotherapy based on naturally circulating dendritic cells","volume":"7","author":"Bol","year":"2019","journal-title":"J Immunother Cancer"},{"key":"2025120413262961000_15.11.e102184.20","doi-asserted-by":"crossref","DOI":"10.1186\/s40425-019-0787-6","article-title":"Blood-derived dendritic cell vaccinations induce immune responses that correlate with clinical outcome in patients with chemo-naive castration-resistant prostate cancer","volume":"7","author":"Westdorp","year":"2019","journal-title":"J Immunother Cancer"},{"key":"2025120413262961000_15.11.e102184.21","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-12-2583"},{"key":"2025120413262961000_15.11.e102184.22","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20092140"},{"key":"2025120413262961000_15.11.e102184.23","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2019-000474","article-title":"Vaccine efficacy against primary and metastatic cancer with in vitro-generated CD103+ conventional dendritic cells","volume":"8","author":"Zhou","year":"2020","journal-title":"J Immunother Cancer"},{"key":"2025120413262961000_15.11.e102184.24","doi-asserted-by":"publisher","DOI":"10.1111\/imm.12888"},{"key":"2025120413262961000_15.11.e102184.25","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-024-45358-0","article-title":"Adjuvant dendritic cell therapy in stage IIIB\/C melanoma: the MIND-DC randomized phase III trial","volume":"15","author":"Bol","year":"2024","journal-title":"Nat Commun"},{"key":"2025120413262961000_15.11.e102184.26","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.06.478"},{"key":"2025120413262961000_15.11.e102184.27","first-page":"198","article-title":"Multiplex Immunohistochemical Analysis of the Spatial Immune Cell Landscape of the Tumor Microenvironment","volume":"2023","author":"Gorris","year":"2023","journal-title":"J Vis Exp"},{"key":"2025120413262961000_15.11.e102184.28","doi-asserted-by":"publisher","DOI":"10.1097\/IGC.0b013e3182070f17"},{"key":"2025120413262961000_15.11.e102184.29","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2024.2412876","article-title":"Trial watch: anticancer vaccination with dendritic cells","volume":"13","author":"Borges","year":"2024","journal-title":"Oncoimmunology"},{"key":"2025120413262961000_15.11.e102184.30","doi-asserted-by":"crossref","DOI":"10.1186\/s40425-019-0565-5","article-title":"Effective cancer immunotherapy by natural mouse conventional type-1 dendritic cells bearing dead tumor antigen","volume":"7","author":"Wculek","year":"2019","journal-title":"J Immunother Cancer"},{"key":"2025120413262961000_15.11.e102184.31","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2021.1935557","article-title":"Cisplatin inhibits frequency and suppressive activity of monocytic myeloid-derived suppressor cells in cancer patients","volume":"10","author":"Van Wigcheren","year":"2021","journal-title":"Oncoimmunology"},{"key":"2025120413262961000_15.11.e102184.32","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2024.1368103","article-title":"Dendritic cell vaccination combined with carboplatin\/paclitaxel for metastatic endometrial cancer patients: results of a phase I\/II trial","volume":"15","author":"Koeneman","year":"2024","journal-title":"Front Immunol"},{"key":"2025120413262961000_15.11.e102184.33","doi-asserted-by":"publisher","DOI":"10.1111\/imm.12036"},{"key":"2025120413262961000_15.11.e102184.34","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-08-2729"}],"container-title":["BMJ Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bmjopen-2025-102184","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,4]],"date-time":"2025-12-04T21:27:48Z","timestamp":1764883668000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmjopen.bmj.com\/lookup\/doi\/10.1136\/bmjopen-2025-102184"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11]]},"references-count":34,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2025,11,9]]},"published-print":{"date-parts":[[2025,11]]}},"alternative-id":["10.1136\/bmjopen-2025-102184"],"URL":"https:\/\/doi.org\/10.1136\/bmjopen-2025-102184","relation":{},"ISSN":["2044-6055","2044-6055"],"issn-type":[{"value":"2044-6055","type":"print"},{"value":"2044-6055","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11]]}}}